Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow up

ASH 2024

Lymphoma

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Lymphoma

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

J Clin Oncol

Jain MD, Spiegel JY, Nastoupil LJ, Tamaresis J, Ghobadi A, Lin Y, Lekakis L, Reagan P, Oluwole O, McGuirk J, Deol A, Dorritie KA, Sehgal AR, Goy A, Hill BT, Andreadis C, Munoz J, Ulrickson M, Westin J, Chavez JC, Patel D, Jacobs MT, Bansal R, Bennani NN, Patel VG, Rapoport AP, Vose JM, Miklos DB, Neelapu SS, Locke FL, Lunning M, Dahiya S

doi: 10.1200/JCO.23.02786

Lymphoma

Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity

Blood

Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC

doi: 10.1182/blood.2023023447

Lymphoma

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Haematologica

Zelikson V, Gurumurthi A, Sawalha Y, Annunzio K, Saha A, Dong N, Qualls D, Amoozgar B, Kahl B, Baird J, Challa P, Huntington SF, Santos J, Bair S, Narkhede M, Li S, Frosch Z, Ho C, Smith SD, Winter A, Landsburg D, Furqan F, Hamadani M, Baird K, Romancik J, Alharthy H, Law J, Bojanini L, Advani R, Hu B, Johnson PC, Grover NS, Merril M, Crombie JL, Shafagati N, Sterling C, Nastoupil LJ, Epperla N, Ayers EC

doi: 10.3324/haematol.2024.285977

ASH 2024

Lymphoma

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

Lymphoma

Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis

Blood

Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ

doi: 10.1182/blood.2023023419

SPECIAL REPORT

Lymphoma

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Lymphoma

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Leuk Lymphoma

Crombie JL, Jun M, Wang T, Mutebi A, Wang A, Chhibber A, Kamalakar R, Ukropec J, Blaedel J, Kalsekar A

doi: 10.1080/10428194.2024.2371472

Lung, Respiratory and Thoracic Cancer

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Front Oncol

Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Léna H, Bosquet L, Girard N, Schoemaker MJ, Mella M, Pinto Correia B, Rault C, Daumont MJ, Penrod JR, Lee A, Pérol M

doi: 10.3389/fonc.2025.1526931

Related content

A Real-World Comparison of Commercial Use Axi-Cel and Liso-Cel in Patients with Large B-Cell Lymphoma

Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity

Loncastuximab in high-risk and heavily pretreated relapsed / refractory diffuse large B-cell lymphoma: a real-world analysis from 21 US centers

Real-world data demonstrate high efficacy of second-line axi-cel in patients with relapsed/refractory large B-cell lymphoma

Comparison of CAR T-cell vs. bispecific antibody as third- or later-line large B-cell lymphoma therapy: A Meta-analysis

Real-World Comparison of YESCARTA® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL

Real-world outcomes with novel therapies in relapsed/refractory diffuse large B-cell lymphoma

Real-world treatment and retreatment patterns and outcomes in patients with advanced or metastatic non-small cell lung cancer following nivolumab monotherapy in second line or later in France: an I-O Optimise analysis

Real-World Comparison of YESCARTA^® and Liso-Cel in 2L+ Among Patients with R/R DLBCL and HGBL